FLT3 inhibitors for acute myeloid leukemia.
作者信息
Lancet Jeffrey E
机构信息
Moffitt Cancer Center, University of South Florida College of Medicine, Tampa, Florida.
出版信息
Clin Adv Hematol Oncol. 2015 Sep;13(9):573-5.
PMID:26452187
Abstract
摘要
相似文献
1
FLT3 inhibitors for acute myeloid leukemia.
Clin Adv Hematol Oncol. 2015 Sep;13(9):573-5.
2
The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Hematol Oncol Clin North Am. 2017 Aug;31(4):663-680. doi: 10.1016/j.hoc.2017.03.002. Epub 2017 May 17.
3
FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):543-549. doi: 10.1016/j.clml.2016.06.002. Epub 2016 Jun 25.
4
The Future of Targeting FLT3 Activation in AML.
Curr Hematol Malig Rep. 2017 Jun;12(3):153-167. doi: 10.1007/s11899-017-0381-2.
5
FLT3 inhibitors in acute myeloid leukemia: Current and future.
J Oncol Pharm Pract. 2019 Jan;25(1):163-171. doi: 10.1177/1078155218802620. Epub 2018 Sep 30.
6
FLT3 Inhibitors in the Management of Acute Myeloid Leukemia.
Anticancer Agents Med Chem. 2017;17(8):1028-1032. doi: 10.2174/1871520616666161010162737.
7
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment.
Hematol Oncol Clin North Am. 2017 Aug;31(4):681-692. doi: 10.1016/j.hoc.2017.04.005. Epub 2017 May 18.
8
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
J Hematol Oncol. 2020 Nov 19;13(1):155. doi: 10.1186/s13045-020-00992-1.
9
FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
Crit Rev Oncog. 2012;17(2):199-209. doi: 10.1615/critrevoncog.v17.i2.50.
10
A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Leuk Res. 2010 Oct;34(10):e268-9. doi: 10.1016/j.leukres.2010.03.046. Epub 2010 Apr 24.
引用本文的文献
1
Clinical use of FLT3 inhibitors in acute myeloid leukemia.
Onco Targets Ther. 2018 Oct 16;11:7041-7052. doi: 10.2147/OTT.S171640. eCollection 2018.
Zotero 插件